Literature DB >> 30898837

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Lisa Ehlers1, Johan Askling2, Hans Wj Bijlsma3, Maria Cinta Cid4, Maurizio Cutolo5, Bhaskar Dasgupta6, Christian Dejaco7,8, William G Dixon9, Nils Feltelius10,11, Axel Finckh12, Kate Gilbert13, Sarah Louise Mackie14, Alfred Mahr15, Eric L Matteson16, Lorna Neill17, Carlo Salvarani18, Wolfgang A Schmidt19, Anja Strangfeld20, Ronald F van Vollenhoven21, Frank Buttgereit22.   

Abstract

Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. A multidisciplinary EULAR task force group of 20 experts including rheumatologists, internists, epidemiologists and patient representatives was assembled. During a 1-day meeting, breakout groups discussed items from a previously compiled collection of parameters describing GCA status and disease course. Feedback from breakout groups was further discussed. Final consensus was achieved by means of several rounds of email discussions after the meeting. A three-round Delphi survey was conducted to determine a core set of parameters including the level of agreement. 117 parameters were regarded as relevant. Potential items were subdivided into the following categories: General, demographics, GCA-related signs and symptoms, other medical conditions and treatment. Possible instruments and assessment intervals were proposed for documentation of each item. To facilitate implementation of the recommendations in clinical care and clinical research, a minimum core set of 50 parameters was agreed. This proposed core set intends to ensure that relevant items from different GCA registries and databases can be compared for the dual purposes of facilitating clinical research and improving clinical care. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Adverse Events, Antirheumatic Agents; methods, Giant Cell Arteritis, Glucocorticoids, Polymyalgia Rheumatica, Registries, Rheumatic Disease and Risk, Treatment Outcome; therapeutic use, Biomedical Research

Mesh:

Year:  2019        PMID: 30898837     DOI: 10.1136/annrheumdis-2018-214755

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

Authors:  Cyril Dumain; Jonathan Broner; Erik Arnaud; Emmanuel Dewavrin; Jan Holubar; Myriam Fantone; Benoit de Wazières; Simon Parreau; Pierre Fesler; Philippe Guilpain; Camille Roubille; Radjiv Goulabchand
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 2.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

3.  A Critical Look at Race-Based Practices in Rheumatology Guidelines.

Authors:  Rose McKeon Olson; Candace H Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-07-07       Impact factor: 5.178

4.  The relationship between glycated haemoglobin levels and the risk of giant cell arteritis - a case-control study.

Authors:  Chetan Mukhtyar; Holly Myers; Colin Jones; Ketan Dhatariya
Journal:  Rheumatol Adv Pract       Date:  2020-05-28

Review 5.  Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides.

Authors:  Valentin Sebastian Schäfer; Lei Jin; Wolfgang Andreas Schmidt
Journal:  Curr Rheumatol Rep       Date:  2020-09-21       Impact factor: 4.592

6.  EULAR recommendations for a core data set for pregnancy registries in rheumatology.

Authors:  Yvette Meissner; Rebecca Fischer-Betz; Laura Andreoli; Nathalie Costedoat-Chalumeau; Diederik De Cock; Radboud J E M Dolhain; Frauke Forger; Doreen Goll; Anna Molto; Catherine Nelson-Piercy; Rebecca Özdemir; Luigi Raio; Sebastian Cruz Rodríguez-García; Savino Sciascia; Marianne Wallenius; Astrid Zbinden; Angela Zink; Anja Strangfeld
Journal:  Ann Rheum Dis       Date:  2020-10-14       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.